5 Stocks to Watch: Week of 11/10/2025

Hey. We hand-picked some of the top-rated stocks from our Zen Ratings system to consider for your watchlist next week, including: 

• Gilead Sciences (GILD) turns scientific wins into serious investor momentum
• Emcor Group (EME) has gained over 85% since we first alerted. Are you watching? 
• Past Stock of the Week selection Flex (FLEX) is back on the list 
• Criteo S.A. (CRTO) scores high marks for Value potential 
• Why Indivior (INDV) has extremely strong analyst support right now

Let’s get to it. (Missed last week’s picks? Get 'em here.)

A note from our sponsors...

1- Emcor Group (NYSE: EME)

Emcor is a leading specialty construction firm with expertise in power transmission, voice & data communications, and fiber optics. It also just so happens to be part of our market-beating Zen Investor portfolio — a pick that has gained 92% since we first alerted. The company is riding some serious growth trends — and the stock’s already impressive rally isn’t showing any signs of stopping.

Zen Rating: A (Strong Buy) — see full analysis  

Recent Price: $675.78 — get current quote  

Max 1-year forecast: $800.00

Why we're watching:  

• Smart money is digging EME, as evidenced by 10 Strong Buy, 5 Buy ratings among the analysts we track. See the ratings
• Analyst commentary emphasizes EMCOR’s 51.5% annual return, robust momentum, and leadership in complex infrastructure.
• A-Rated Industry: The Engineering & Construction Industry is among the top-rated market niches we track; EME is the 8th highest-rated stock out of 45. 
• An excellent Zen Rating: With its Strong Buy (A) rating, EME is in a class of stocks that have enjoyed +32.52% returns per year. 
• Key areas of strength as revealed by the Component Grades include Growth and Momentum, where EME earns above-average Bs, ranking in the top 25% of stocks, indicating there’s more gas in the tank for this high-potential ticker. (See all 7 Zen Component Grades here)

2- Gilead Sciences (NASDAQ: GILD)

Gilead Sciences isn’t resting on its laurels. With powerhouse HIV treatments fueling growth, new cancer drugs earning headlines, and a robust R&D engine firing on all cylinders, this biotech leader is turning scientific wins into serious investor momentum.

Zen Rating: B (Buy) — see full analysis  

Recent Price: $120.75 — get current quote  

Max 1-year forecast: $150.00 

Why we're watching:  

• Strong analyst support: Among the top-rated analysts we track, GILD enjoys 18 Strong Buy, 9 Buy, and 6 Hold ratings. See the ratings
• Wells Fargo researcher John Smith recently raised the price target after Gilead's HIV franchise outperformed in Q3 and the company won the 2025 Prix Galien award for Yeztugo® (Lenacapavir), citing "Transformation in blood cancer care and consistent pipeline execution should support further upside."
• Strong price action: Gilead has enjoyed a 7% surge in the past month and 30%+ annual gains 
• Industry ranking context: GILD is currently the 7th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A. (See more winners in the industry here)
• With a Zen Rating of B (Buy), GILD is in good company — B-rated stocks have historically delivered +19.88%/yr.
• The Component Grades shaping that overall rating show specific areas of strength: GILD has above-average rankings for Financials, Safety, and Value. (See all 7 Zen Component Grades here)

A note from our sponsors...

3- Flex (FLEX)

Flex helps design, build, and deliver products and entire supply chains across a wide variety of industries, including automotive, healthcare, and even cloud computing. It also happens to be a past Stock of the Week. Right now, this is one of the highest-rated stocks in the tech sector — as well as one of the best-rounded stocks we track overall.

Zen Rating: B (Buy) — see full analysis  

Recent Price: $61.13 — get current quote  

Max 1-year forecast: $78.00

Why we're watching:  

• It’s a repeat pick: Stocks with a proven history of outperformance are worth watching — after all, history doesn’t repeat, but it rhymes. We first alerted FLEX in September, when our Editor-in-Chief, Steve Reitmeister, explained why the stock deserved inclusion in his exclusive, 20-stock strong Zen Investor portfolio. (It’s gained 22% since it was added.)
• Analyst support: Currently, FLEX enjoys ONLY Strong Buy ratings among the analysts we track — no Hold, Sell, or Strong Sell ratings. See the ratings
• JP Morgan's Samik Chatterjee (a top 1% analyst) highlighted Flex as a "major beneficiary of the accelerating AI race," leading to a target increase after Q2 results topped forecasts.
• Solid industry: FLEX is in the A-rated Electronic Component industry, ranking in the top third of the 36 stocks in this niche. 
• With a Zen Rating of B, FLEX is in a class of stocks that have historically delivered 19.88% annual returns. 
• Looking at the Component Grades, FLEX scores highly in several noteworthy areas: Momentum, Safety, and Sentiment, suggesting it’s a great pick for investors looking for security and the potential for impressive price action. (See all 7 Zen Component Grades here)

4- Criteo S.A. (NASDAQ: CRTO)

Criteo S.A. delivers technology-driven digital marketing and monetization services worldwide, leveraging AI and deep consumer data to drive results for online advertisers. The stock is surging after strong Q3 earnings, a planned redomicile to Luxembourg, and a leadership refresh with a new Chief Customer Officer.

Zen Rating: A (Strong Buy) — see full analysis  

Recent Price: $21.62 — get current quote  

Max 1-year forecast: $51.00

Why we're watching:  

• Analyst support: CRTO currently enjoys a Buy consensus among the analysts we track, with 4 Strong Buy, 1 Buy, and 3 Hold ratings. See the ratings
• Highlights among analyst coverage include a turnaround in quarterly earnings, and suggest the stock is trading well below intrinsic value.
• Industry ranking context: CRTO is the top-rated stock in the Advertising Agency sector (Industry Rating: B; 28 companies).
• With a Zen Rating of A (Strong Buy), CRTO is in the top 5% of stocks we track based on a rigorous 115-factor review. 
• The Component Grades grading key factors within that review suggest it may be an excellent Value (it’s rated in the top 5% of stocks we track in this category). Additionally, our proprietary AI factor, which has been trained to sniff out the highest-potential stocks (see how it works here) has identified CRTO as an above-average pick. (See all 7 Zen Component Grades here)

5- Indivior PLC (NASDAQ: INDV)

Here’s an interesting niche: INDV manufactures therapies for opioid dependence and related co-occurring conditions. The company is experiencing rapid growth after a significant Q3 earnings beat, strong guidance, and favorable regulatory catalysts.

Zen Rating: A (Strong Buy) — see full analysis  

Recent Price: $30.75 — get current quote  

Max 1-year forecast: $41.00

Why we're watching:

• Analyst support: INDV only has Buy or Strong Buy ratings among the analysts we track. No Hold, Sell, or Strong Sell ratings here. See the ratings here
• Commentary from several firms focuses on the real-world evidence supporting product adherence and economic benefits — and, of course, the company’s recent earnings beat. 
• Industry ranking context: INDV currently ranks #3 of 57 in the Pharmaceutical industry, with the sector holding a solid B rating.
• INDV has a Zen Rating of A, indicating it’s one of the strongest stocks in the 4600+ catalog of tickers we track. 
• Looking at the Component Grades, INDV has a top-tier grade for Sentiment (A, top 5%), and impressive Value (B) and Financials (B) grades. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.